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Summary
 
Heat shock proteins (hsp’s) isolated from murine cancer cells can elicit protective immunity
and specific cytotoxic T lymphocytes (CTLs) by channeling tumor-derived peptides bound to
hsp’s to the major histocompatibility class I antigen presentation pathway. Here we have inves-
tigated if hsp70 can be used in a novel peptide vaccine for the induction of protective antiviral
immunity and memory CTLs. A CTL epitope from the well-defined lymphocytic choriomen-
ingitis virus (LCMV) system was mixed with recombinant hsp70 in vitro under conditions that
optimize peptide binding to hsp70. Mice were immunized with the hsp70–peptide mixture
and challenged with LCMV. Virus titers were reduced 10–100-fold in these mice compared to
control mice. Immunization with the hsp70–peptide mixture resulted in the development of
CTL memory cells that could be reactivated during LCMV infection, and that in a 
 
51
 
Cr-release
assay could lyse cells pulsed with the same peptide, but not cells pulsed with another LCMV
peptide. These results show that hsp70 can be used with CTL epitopes to induce efficient pro-
tective antiviral immunity and the generation of peptide-specific CTLs. The results also dem-
onstrate the usefulness of hsp70 as an alternative to adjuvants and DNA vectors for the delivery
of CTL epitopes to antigen-presenting cells.
 
H
 
eat shock protein 70 (hsp70)
 
1
 
 is a member of a family
of molecular chaperones important in protein synthe-
sis and folding. The constitutively expressed cytosolic member
of this family assists the folding of newly synthesized
polypeptides into their correct conformation by binding to
them during protein synthesis. It also assists in the translo-
cation of proteins across membranes into different com-
partments of the cell. When the cell is stressed, the induc-
ible cytosolic member of the hsp70 family is synthesized,
preventing proteins from aggregating and in this way en-
hancing the survival of the cell. Binding to both the consti-
tutive and the inducible members of hsp70 is a step on the
way to degradation of a protein that has become too dena-
tured to be rescued (1, 2).
Hsp70 is among the most conserved and abundant pro-
teins within a cell. Because of its role in protein synthesis, it
is an essential molecule for the survival of the normal cell as
well as for synthesis of new viral proteins in a virus-infected
cell. To be able to perform its tasks, hsp70 has a broad
binding specificity. In order for it to bind a peptide, the
peptide needs to have a hydrophobic region of more than
six amino acids with both small and large hydrophobic
amino acids (3–5).
Bacterial hsp’s have been long known to stimulate the
host immune response, e.g., as a component in Freund’s
complete adjuvant. Efforts have been made to use hsp’s as
carrier proteins without additional adjuvants. Recently, Su-
zue and Young showed that antibody and cytokine pro-
duction as well as lymphocyte proliferation were elicited in
mice immunized with mycobacterial hsp70 covalently
bound to the HIV-1 p24 protein (6). Román and Moreno
showed that by immunizing mice with mycobacterial
 
1
 
Abbreviations used in this paper:
 
 GP, glycoprotein; hsp, heat shock protein;
LCMV, lymphocytic choriomeningitis virus; rhsp 70, recombinant hu-
man hsp70; VSV, vesicular stomatitis virus.
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hsp70 noncovalently bound to the MHC class II influenza
A peptide (pNP 206–229), proliferative T cell responses
were elicited to the hsp70-binding peptide (7). In both of
these studies, the bacterial hsp70 was used as a carrier pro-
tein. It is presumed that the hsp70 and its bound peptide or
protein are taken up into the endosomal compartment of
APCs, that they go through the exogenous processing
pathway, and that the peptides get presented on MHC class
II molecules.
It is well established that extracellular proteins are pro-
cessed through the exogenous processing pathway and are
presented on MHC class II molecules, but they do not
have access to the endogenous processing pathway. This
rule seems to be overcome in experiments where immuni-
zations with hsp’s isolated from murine cancer cells have
been shown to elicit antitumor immunity in vivo and tu-
mor-specific CTLs in vitro (8–10). The antitumor protec-
tion in these experiments was shown to depend on peptides
binding to the hsp’s purified from tumor tissue, and the re-
sults imply the use of an exogenous class I pathway. In a
similar way, CTLs specific for a vesicular stomatitis virus
(VSV) peptide were generated by immunizing mice with
another hsp, gp96, purified from VSV-infected cells. Mac-
rophages were shown to take up the bound peptide and
present it on the MHC class I molecules of the macro-
phages to cytotoxic T cells (10).
These experiments showing the induction of class I–restricted
CD8
 
1
 
 T cell responses against tumors or viruses after im-
munization with hsp from tumor or virus-infected cells led
us to hypothesize that protective antiviral T cell responses
might be induced by immunization with defined viral im-
munodominant T cell peptides conjugated to hsp’s.
In this study, we investigated if hsp70 could be used to
induce CTL-dependent protection to a viral infection in
vivo. We asked if a peptide mixed in vitro with hsp70 and
provided exogenously by immunization in mice would in-
duce a protective CTL response. If so, this would show
that the peptide is presented on MHC class I molecules.
This ability would be of great importance in the design of
new peptide vaccines, and could give us an insight into to
what degree the endogenous antigen processing and pre-
sentation pathway is restricted to the origin of the antigen.
We therefore mixed viral peptides from the well-defined
lymphocytic choriomeningitis virus (LCMV) system (11–
13) with recombinant human hsp70 (rhsp70) in vitro and
immunized mice with the rhsp70–peptide mixture. This
evoked protective antiviral immunity measured in a virus
plaque assay and specific CTLs measured in a 
 
51
 
Cr-release
assay.
 
Materials and Methods
 
Mice.
 
C57BL/6 (H-2
 
b
 
) male mice were purchased from The
Jackson Laboratory (Bar Harbor, ME) and were used at 1–6 mo
of age.
 
Viruses.
 
The Armstrong strain of LCMV was used in all ex-
periments. The virus was propagated in BHK21 baby hamster
kidney cells (14).
 
Cell lines.
 
MC57G (H-2
 
b
 
), a methylcholanthrene-induced
sarcoma from C57BL/6 mice, was propagated in Eagle’s MEM
(Gibco Laboratories, Life Technologies Ltd., Paisley, U.K.) sup-
plemented with 100 U/ml penicillin G, 100 
 
m
 
g/ml streptomycin
sulfate, 2 mM 
 
l
 
-glutamine, and 10% heat-inactivated fetal bovine
serum. Vero, an African green monkey kidney cell line used in
plaque assays, was propagated in MEM as above. The RMA-S
cell line was derived from a Rauscher leukemia virus–induced T
cell lymphoma, RBL-5, of B6 origin (H-2
 
b
 
; 15) and cultured in
RPMI medium (Sigma Chemical Co., St. Louis, MO) supple-
mented as above.
 
Peptides, hsp70, and Binding/Mixing Procedure.
 
Three previ-
ously described LCMV peptides were used (12, 13, 16). Two of
the peptides were from the LCMV glycoprotein (GP): peptide
33–40 (KAVYNFAT), here called 8mer, and peptide 33–45
(KAVYNFATCGIFA), here called 13mer. The third peptide was
the ribonucleoprotein peptide 397–407 (QPQNGQFIHFY),
here called NP. The 8mer and 13mer were synthesized at the
peptide synthesis facility at Microbiology and Tumorbiology
Center, Karolinska Institute (Stockholm, Sweden), by a solid-
phase method using Fmoc chemistry. The NP peptide was syn-
thesized and HPLC-purified by Dr. Robert Carroway at the
University of Massachusetts peptide core facility.
The rhsp70 was produced and purified as previously described
(17). The peptide binding activity of this rhsp70 has been assessed
by a competition assay, in which an unfolded form of lactalbumin
was complexed to rhsp70. Addition of an excess of a 7-amino
acid-long peptide competed out the lactalbumin, showing that
the rhsp70 used is entirely in the native form that can and does
bind peptides (17). In accordance to the protocol described in
Jindal et al. (17), the peptides were incubated with rhsp70 or BSA
(Sigma Chemical Co.) in binding buffer (PBS with 2 mM
MgCl
 
2
 
) at 37
 
8
 
C for 60 min. Then 0.5 mM ADP (Sigma Chemi-
cal Co.) was added and the incubation was continued for another
60 min at the same temperature. This protocol method was also
consistent with those of others (4, 5, 18, 19). Lactoferrin (Sigma
Chemical Co.) was incubated with peptide in binding buffer on
ice for 60 min.
 
Immunizations.
 
Mice were immunized with 2 
 
m
 
g peptide
(8mer or 13mer), rhsp70, BSA, or lactoferrin; with 2 
 
m
 
g peptide
mixed with 2 
 
m
 
g of rhsp70, BSA, or lactoferrin; or with binding
buffer only. The immunizations were done intraperitoneally,
three times at 2-wk intervals (experiment 1) or two times at 3-wk
intervals (experiments 2 and 3). 2 (experiment 1) or 3 (experi-
ments 2 and 3) wk after the last immunization the mice were in-
oculated intraperitoneally with 5 
 
3
 
 10
 
4
 
 PFU of LCMV, and on
day 3 or 5 after infection the spleens were harvested. Nonimmu-
nized mice were killed on day 8 after infection for detection of
the peak CTL response.
 
Cytotoxicity assay.
 
A standard microcytotoxicity assay was
used to determine CTL activity (20). RMA-S cells incubated
with 8mer or NP peptides or with MC57G cells infected with
LCMV were pelleted, resuspended in 100 
 
m
 
Ci of Na-
 
51
 
Cr per
10
 
6
 
 cells (Amersham Corp., Arlington Heights, IL), and incubated
for 1 h at 37
 
8
 
C in a humidified 5% CO
 
2
 
 incubator. The cells were
rinsed three times and resuspended to 10
 
5
 
/ml, and 0.1 ml of the cell
preparation was added to round-bottomed microtiter wells. Vary-
ing numbers of effector leukocytes were added in triplicate in 0.1
ml of medium to achieve the desired E/T ratio. For spontaneous
 
51
 
Cr-release, 0.1 ml of media was added to the labeled target cells
in place of effectors. For maximum 
 
51
 
Cr-release, 0.1 ml of 1%
NP-40 (United States Biochemical Co., Cleveland, OH) was
added to the labeled target cells. After 6 h at 37
 
8
 
C in a 5% CO
 
2 
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incubator, the microtiter plates were centrifuged at 200 
 
g
 
 for 5
min. Supernatants were removed (0.1 ml) from each well and
counted on a gamma counter (model 5000; Beckman Instru-
ments, Inc., Fullerton, CA). Data are expressed as follows: per-
centage of specific 
 
51
 
Cr-release 
 
5
 
 100 
 
3
 
 [(experimental cpm 
 
2
 
spontaneous cpm) / (maximum release cpm 
 
2
 
 spontaneous re-
lease cpm)]. The killing of noninfected or nonpulsed cells was
subtracted from the pulsed or infected cell data, thus giving the
percentage of specific killing.
 
Virus Titer Assay.
 
Spleens from immunized mice were ho-
mogenized and centrifuged at 400 
 
g
 
 for 15 min. Supernatants
were titrated for virus plaques on Vero cell monolayers.
 
Results
 
Protective Anti-LCMV Immunity in Mice Immunized with
hsp70–Mixed Peptide.
 
We evaluated if mixing of the 8mer
or the 13mer of the GP 33 LCMV epitope with rhsp70
would enhance resistance of immunized mice to challenge
with LCMV-Armstrong. For hsp70 to bind a peptide to its
peptide-binding groove, the peptide needs to have a hy-
drophobic region of more than 6 amino acids. The 8mer, a
well-defined MHC class I epitope, and the 13mer, an elon-
gation of the 8mer with five additional amino acids, each
have both small and large hydrophobic amino acids, re-
quired for binding to hsp70 (3–5). A 70:1 molar ratio of
peptide/protein was chosen to facilitate the chance of most
of the rhsp70 molecules binding to the LCMV peptide, ac-
cording to what we had previously (17) found to be an op-
timal condition for peptide binding using the same source
of rhsp70. After 1 h, 0.5 mM of ADP was added, as ADP
greatly enhances the ability of hsp70 to bind to peptides (18). 
Mice immunized with LCMV immunodominant pep-
tides with or without prior mixing of the peptides with
rhsp70 were challenged with LCMV, and viral titers in the
spleens were determined by plaque assays 3 or 5 d after in-
fection (Fig. 1).
In the first experiment, mice were immunized three
times at 2-wk intervals before challenge with virus. At day
3 after challenge, immunization with the 8mer provided no
protection compared to the buffer or rhsp70 controls,
whereas immunization with the hsp70-mixed bound 8mer
resulted in titers 0.8 log lower than that of rhsp70 alone. By
day 5 after infection, immunization with the hsp70-mixed
8mer resulted in nearly total clearance of virus, with 
 
.
 
100-
fold clearance in comparison to rhsp70-only or 8mer-only
controls. One of the two mice immunized only with buffer
had cleared virus, but this was considered an anomaly, as
the other mouse had a titer similar to the rhsp70-only and
8mer-only controls, and clearance by buffer-immunized
mice was not seen in any other experiment.
The immunization scheme was shortened in the second
and third experiments, where mice were immunized only
twice before challenge with virus. Again, rhsp70 greatly
enhanced the immunization capacity of the 8mer, as sub-
stantial reductions in viral titers at days 3 and 5 after infec-
tion occurred in mice immunized with the hsp70-mixed
8mer. Compared to buffer-only, 8mer-only, or rhsp70-
only controls, as high as 10–100-fold reductions in viral ti-
ters were observed. In neither experiment did the 8mer
alone immunize against the viral infection. As an additional
control, in some experiments peptides were preincubated
with BSA or human lactoferrin under conditions similar to
that used with rhsp70. Neither BSA nor lactoferrin en-
hanced the immunization capacity of the peptides.
Similar experiments were also done with the 13mer,
which was an elongated form of the 8mer. Immunization
with the 13mer alone resulted in greater than a tenfold re-
duction in viral titers at days 3 or 5 after infection in all
Figure 1. In vivo resistance to
challenge with LCMV. Mice
immunized with 8mer, rhsp70,
or 8mer mixed with BSA have
high virus titers after challenge
with LCMV, whereas mice im-
munized with rhsp70-mixed
8mer have 8–100-fold lower vi-
rus titers. (a) Experiment 1, day 3
after infection with LCMV (n 5
3). (b) Experiment 1, day 5 after
infection (n 5 2). (c) Experiment
2, day 3 (n 5 3). (d) Experiment
2, day 5 (n 5 2). (e) Experiment 3,
day 5 (n 5 3 or 4) N.D. 5 not
done. Bars show the standard de-
viation. 
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three experiments, and coimmunization with rhsp70 did
not enhance the protective effect except in experiment 2,
day 5 (Fig. 2). Thus, the hsp70 enhanced the protective
immunity induced by the minimal T cell epitope but was
unnecessary for immunization by the more complex
epitope.
 
Immunization with rhsp70-mixed Peptide Primes for LCMV-
specific CTLs.
 
We next evaluated if the enhanced protec-
tion induced by the GP 33–derived peptides, when mixed
with rhsp70, would be associated with an induction of spe-
cific CTLs. The CTL response to LCMV normally peaks at
days 7–9 after infection in nonimmunized mice, but occurs
on days 4 to 5 in mice previously immunized with virus
(11, 20). We have found that in primary infections some
CTL activity can be detected on the highly sensitive pep-
tide-pulsed RMA-S targets 5 d after infection, whereas less
killing can be detected against conventional virus-infected
MC57G cell targets. For the following experiments we ex-
amined CTL killing on day 5 against both virus-infected
MC57G targets and peptide-pulsed RMA-S targets.
Our results demonstrated that spleen cells from mice im-
munized with the rhsp70-mixed 8mer were significantly
more efficient in lysing 8mer-pulsed RMA-S cells, as com-
pared to spleen cells from mice immunized with peptide
alone, with buffer, or with rhsp70 alone (Fig. 3 
 
a
 
). Simi-
larly, mice immunized with the 13mer peptide mixed with
rhsp70 generated significantly higher cytotoxic activity af-
ter challenge than those immunized with 13mer alone,
buffer, or rhsp without peptides (Fig. 3 
 
a
 
). In one experi-
ment, however, high cytotoxic activity on GP33-coated
targets after challenge was obtained with spleen cells from
mice immunized with the 13mer alone without rhsp70.
The 8mer was also mixed with BSA (Fig. 3 
 
c
 
) or lacto-
ferrin (data not shown) as protein carrier controls for the
hsp70. Neither treatment enhanced the ability of the 8mer,
when compared to the 8mer alone, to prime for a CTL re-
sponse after challenge (Fig. 3 
 
c
 
). This is consistent with the
in vivo protection results, which show that those control
carrier molecules had no effect on protective immunity.
RMA-S cells pulsed with the NP peptide of the nuclear
protein of LCMV were used as specificity controls in the
same experiments. Although mice previously immunized
with LCMV elicited a strong anti-NP response after chal-
lenge with LCMV, mice immunized with the GP33 8mer
or 13mer, whether mixed with rhsp70 or not, did not elicit
an enhanced anti-NP CTL response after LCMV challenge
(Fig. 3, 
 
b
 
 and 
 
d
 
). Acutely infected mice 8 d after infection
were tested as positive controls, and their splenocytes me-
diated 
 
.
 
80% killing of RMA-S cells pulsed with either the
GP or NP peptide.
Next, we measured the cytotoxic activity of the spleno-
cytes from the immunized mice on LCMV-infected
MC57G cells, to see if the CTLs we had primed for also
had the ability to lyse the less sensitive virus-infected cells.
The hsp70-mixed 8mer CTLs did lyse the virus-infected
cells at significant levels at day 5 in one experiment, and
some low levels of lysis were detected in the other two ex-
periments as well (data not shown). After immunizing with
the hsp70-mixed 13mer, cytotoxic activity after virus chal-
lenge against LCMV-infected target cells was observed at a
stronger level. Significant increases in cytotoxic activity
were measured with these 13mer hsp70-primed CTLs in
all experiments compared to peptide only, buffer, or hsp70
only controls (Fig. 4). Mice immunized with 13mer hsp70
developed CTL activity as high as did immune mice previ-
ously infected with LCMV on challenge. This suggests that
Figure 2. Immunization with
13mer alone gives resistance to
LCMV challenge. Mice immu-
nized with the 13mer alone had
lower viral titers than did buffer
controls, with or without hsp70
or BSA. (a) Experiment 1, day 3
after infection with LCMV (n 5
3). (b) Experiment 1, day 5 after
infection (n 5 2). (c) Experiment
2, day 3 (n 5 3). (d) Experiment
2, day 5 (n 5 2) (e) Experiment 3,
day 5 (n 5 3 or 4) N.D. 5 not
done. Bars show the standard de-
viation. 
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immunizing with the hsp70-mixed 13mer would be as ef-
fective in priming for LCMV-specific CTLs as would a vi-
ral infection.
 
Discussion
 
We show that it is possible to induce protective immu-
nity to LCMV with a low dose of a minimal T cell epitope
if the peptide is mixed with hsp70, without the need of ad-
ditional adjuvants. To our knowledge this is the first time
in vivo protection to an infectious agent has been shown
by immunization with a peptide–hsp complex. The protec-
tion shown here implies that the complexing of peptide to
hsp70 has resulted in a more efficient CTL induction, as
protection in the LCMV system is dependent on CTLs
(21), particularly when immunization is carried out in the
absence of neutralizing antibody epitopes. We next show
that the enhanced in vivo protection was indeed associated
with a more efficient induction of virus-specific CTLs on
LCMV challenge. These CTLs are specific for the LCMV
peptide with which we immunized and did not recognize
another LCMV peptide, showing the specificity of the sys-
tem. Hence, complexing of the peptide to hsp70 is likely to
have resulted in a more efficient presentation of the peptide
on the MHC class I complex on the cell surface of APCs.
Mixing of the peptide with either of the carrier proteins
BSA or lactoferrin did not result in enhanced in vivo pro-
tection or CTL generation when tested in vitro. Thus the
effect of hsp70 is not a general response to any additional
protein in the immunization protocol, but is specific to the
properties of the hsp molecule. Such properties could in-
volve both the known capacity of hsp70 in binding to pep-
tides, as well as endowments of the protein we have yet to
discover.
Our results indicate that exogenous antigens may play an
important roles in the priming of CTLs. It has been sug-
gested that hsp’s facilitate the delivery of antigenic epitopes
to MHC class I molecules (22). In preliminary experiments
by Blachere et al. (23) and in a pilot experiment with a
small number of animals by Heikema et al. (24), gp96 was
Figure 3. Immunization with hsp70-mixed peptide elicits peptide-specific CTLs 5 d after challenge with LCMV. (a) Immunization with rhsp70-
mixed 8mer or 13mer, but not 8mer or 13mer alone or hsp70 alone, primes for 8mer-specific CTLs. Target: RMA-S pulsed with 8mer. (b) Immuniza-
tion with hsp70-mixed 8mer does not prime for NP-specific CTLs. Target: RMA-S pulsed with NP. BSA cannot replace hsp70. (c) Neither BSA nor
BSA with peptide prime for 8mer-specific CTLs. Target: RMA-S pulsed with 8mer. (d) Immunization with hsp70-mixed or BSA-mixed 8mer does not
prime for NP-specific CTL. Target: RMA-S pulsed with NP peptide. The killing of nonpulsed RMA-S cells has been subtracted from the killing of the
peptide-pulsed cells in all four panels. 
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purified from cells transfected with a gene encoding the se-
quence for a viral peptide from flu-NP or SV40. Spleno-
cytes from mice immunized with this gp96 were shown to
kill target cells transfected with the relevant protein or in-
fected with the relevant virus. Experimental data with gp96
in a VSV system suggest that macrophages take up the hsp
and its bound peptides, resulting in a presentation of the
peptide epitope by the MHC class I molecules of the mac-
rophage to T cells (10). It is not yet known how the hsp is
taken up by APCs in vivo. For gp96 the mannose receptor
has been suggested as a route of uptake by macrophages
(10), but no mechanism has been suggested for the nongly-
cosylated hsp70. The route the peptide takes inside the cell
before reaching the MHC class I molecule is also not yet
known.
We show experimental support for the importance of
hsp’s in CTL priming. Our LCMV model shows that chap-
eroning of the viral peptide by hsp70 results in highly effi-
cient CTL generation and enhanced in vivo resistance to
virus replication, even when given at low doses of peptide
and low doses of hsp70. During revision of this manuscript,
Blachere et al. published data showing binding of a VSV
peptide to gp96 and hsp70 and priming for CD8
 
1
 
 cells.
They also show that gp96 bound to a VSV peptide can protect
against challenge with a VSV-transfected tumor (25). Our
data are consistent with these data, while uniquely showing
that this technique can be used to induce protective antivi-
ral immunity in vivo. Apart from the capacity of “channel-
ing” the peptide to the MHC class I antigen presentation
pathway, hsp70 may also protect the peptide from degrada-
tion. The enhanced in vivo protection was apparent with
the minimal 8mer epitope of GP 33 when mixing it with
hsp70, but it is notable that flanking this peptide with an
additional five amino acids renders it immunogenic in vivo
even when given at a quantity of only 2 
 
m
 
g in the absence
of hsp70. The explanation for this is unclear, but it implies
that the longer peptide epitope may be channeled to the
MHC class I antigen presentation pathway even without
hsp70, or that the 13mer is less vulnerable to degradation.
The latter explanation would emphasize the protective role
of hsp70 in vivo.
Efforts are being made to construct effective peptide-
based vaccines against infectious agents and tumors. Pep-
tides derived from tumor antigens have been shown to
confer protection against tumor growth in murine models
(26), and clinical trials have been initiated using peptides as
immunotherapy in tumor patients (27). The usefulness of
peptide-based vaccines is limited by the need for immuniz-
ing with a large amount of peptide and for effective and
nontoxic adjuvants that also can induce specific CTL re-
sponses. Inefficient antigen presentation of the injected
peptide may even lead to tolerance induction, resulting in
reduced, rather than enhanced, host protection (21, 28).
Using hsp’s purified from infected cells or tumor cells, or as
described here using an rhsp mixed in vitro with defined T
cell epitopes, could considerably facilitate the efficacy of
peptide-based vaccines. As hsp70 is an abundant self-pro-
tein, immunization with the whole protein is not likely to
elicit immune responses to the hsp70 itself because of self
tolerance (7, 29). The amount of peptide necessary to
evoke a protective immune response could be greatly re-
duced, and an additional adjuvant is not required. These
qualities, together with its efficient way of enhancing pro-
tective immunity, may render hsp70 into a good candidate
for use in peptide-based vaccines.
Figure 4. Immunization with
hsp70-mixed 13mer primes for
LCMV-specific CTL activity 5 d
after challenge with the virus.
Immunization with hsp70-mixed
bound 13mer, but not 13mer
alone, hsp70 alone, or peptide
mixed with BSA primes for CTL
activity detected on LCMV-
infected targets. Target: LCMV-
infected cells. The killing of
noninfected MC57G cells has
been subtracted from the killing
of the infected cells.
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